The Bio Report - A Company That Bets Its Therapies Will Click with Patients

One of the underlying limitations of most cancer therapies is the fact that only about 1 to 2 percent of the drug that’s administered ever reaches tumors. Shasqi founder and CEO, José met with Daniel Levine to talk about our CAPAC platform technology, how it works, and why this can lead to safer and more powerful cancer therapies. Listen to the full podcast here